End-stage renal disease in patients with rheumatoid arthritis

Sunita Paudyal, Frances M. Yang, Christopher Rice, Chen Chun Chen, Michael Skelton, Monique Bethel, Shilpa Brown, Norris Stanley Nahman, Laura Carbone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives To determine the frequency of end-stage renal disease (ESRD) in patients with rheumatoid arthritis (RA), the causes of ESRD, and the treatment of RA in the setting of ESRD. Methods Cross-sectional study of RA (N = 3754) and non-RA (N = 326,776) patients in the United States Renal Data System (USRDS) during 2011 (N = 330,530). The epidemiology of ESRD in RA was determined and the etiology of ESRD in patients with and without RA was compared. The frequency of patients with RA with at least one filled prescription for prednisone/prednisolone, a DMARD, and/or a biologic in 2011 was determined. Results The prevalence of RA with ESRD in the USRDS in 2011 was 1.1%. There were significant differences in age, race, sex, and BMI category between the groups (p < 0.01). Diabetes (33.5%) and hypertension (30.6%) were the most common primary causes of ESRD in patients with RA. Amyloidosis, vasculitis, and analgesic nephropathy combined accounted for less than 10% of cases of ESRD. Prednisone was the most commonly filled medication that could be used to treat RA (45.9% of RA patients). Hydroxychloroquine was the most frequently filled DMARD (13.5%); biologics were uncommon (etanercept 2.5%, adalimumab 1.5%; golimumab, infliximab, anakinra, and abatacept <1%). Conclusions The co-occurrence of RA with ESRD was 1.1% in the USRDS by 2011. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Use of DMARDS other than hydroxychloroquine and biologics to treat RA in the setting of ESRD appears to be infrequent. Further prospective studies of treatment strategies for RA in ESRD are needed.

Original languageEnglish (US)
Pages (from-to)418-422
Number of pages5
JournalSeminars in Arthritis and Rheumatism
Volume46
Issue number4
DOIs
StatePublished - Feb 1 2017

Fingerprint

Chronic Kidney Failure
Rheumatoid Arthritis
Information Systems
Hydroxychloroquine
Antirheumatic Agents
Prednisone
Biological Products
Kidney
Interleukin 1 Receptor Antagonist Protein
Hypertension
Amyloidosis
Vasculitis
Prednisolone
Arthritis
Prescriptions
Analgesics
Comorbidity
Epidemiology
Cross-Sectional Studies
Prospective Studies

Keywords

  • Biologics
  • DMARDs
  • End-stage renal disease
  • Prednisone
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

End-stage renal disease in patients with rheumatoid arthritis. / Paudyal, Sunita; Yang, Frances M.; Rice, Christopher; Chen, Chen Chun; Skelton, Michael; Bethel, Monique; Brown, Shilpa; Nahman, Norris Stanley; Carbone, Laura.

In: Seminars in Arthritis and Rheumatism, Vol. 46, No. 4, 01.02.2017, p. 418-422.

Research output: Contribution to journalArticle

Paudyal, Sunita ; Yang, Frances M. ; Rice, Christopher ; Chen, Chen Chun ; Skelton, Michael ; Bethel, Monique ; Brown, Shilpa ; Nahman, Norris Stanley ; Carbone, Laura. / End-stage renal disease in patients with rheumatoid arthritis. In: Seminars in Arthritis and Rheumatism. 2017 ; Vol. 46, No. 4. pp. 418-422.
@article{b276816b8ab9412bacbb6949e449242c,
title = "End-stage renal disease in patients with rheumatoid arthritis",
abstract = "Objectives To determine the frequency of end-stage renal disease (ESRD) in patients with rheumatoid arthritis (RA), the causes of ESRD, and the treatment of RA in the setting of ESRD. Methods Cross-sectional study of RA (N = 3754) and non-RA (N = 326,776) patients in the United States Renal Data System (USRDS) during 2011 (N = 330,530). The epidemiology of ESRD in RA was determined and the etiology of ESRD in patients with and without RA was compared. The frequency of patients with RA with at least one filled prescription for prednisone/prednisolone, a DMARD, and/or a biologic in 2011 was determined. Results The prevalence of RA with ESRD in the USRDS in 2011 was 1.1{\%}. There were significant differences in age, race, sex, and BMI category between the groups (p < 0.01). Diabetes (33.5{\%}) and hypertension (30.6{\%}) were the most common primary causes of ESRD in patients with RA. Amyloidosis, vasculitis, and analgesic nephropathy combined accounted for less than 10{\%} of cases of ESRD. Prednisone was the most commonly filled medication that could be used to treat RA (45.9{\%} of RA patients). Hydroxychloroquine was the most frequently filled DMARD (13.5{\%}); biologics were uncommon (etanercept 2.5{\%}, adalimumab 1.5{\%}; golimumab, infliximab, anakinra, and abatacept <1{\%}). Conclusions The co-occurrence of RA with ESRD was 1.1{\%} in the USRDS by 2011. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Use of DMARDS other than hydroxychloroquine and biologics to treat RA in the setting of ESRD appears to be infrequent. Further prospective studies of treatment strategies for RA in ESRD are needed.",
keywords = "Biologics, DMARDs, End-stage renal disease, Prednisone, Rheumatoid arthritis",
author = "Sunita Paudyal and Yang, {Frances M.} and Christopher Rice and Chen, {Chen Chun} and Michael Skelton and Monique Bethel and Shilpa Brown and Nahman, {Norris Stanley} and Laura Carbone",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.semarthrit.2016.07.016",
language = "English (US)",
volume = "46",
pages = "418--422",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - End-stage renal disease in patients with rheumatoid arthritis

AU - Paudyal, Sunita

AU - Yang, Frances M.

AU - Rice, Christopher

AU - Chen, Chen Chun

AU - Skelton, Michael

AU - Bethel, Monique

AU - Brown, Shilpa

AU - Nahman, Norris Stanley

AU - Carbone, Laura

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Objectives To determine the frequency of end-stage renal disease (ESRD) in patients with rheumatoid arthritis (RA), the causes of ESRD, and the treatment of RA in the setting of ESRD. Methods Cross-sectional study of RA (N = 3754) and non-RA (N = 326,776) patients in the United States Renal Data System (USRDS) during 2011 (N = 330,530). The epidemiology of ESRD in RA was determined and the etiology of ESRD in patients with and without RA was compared. The frequency of patients with RA with at least one filled prescription for prednisone/prednisolone, a DMARD, and/or a biologic in 2011 was determined. Results The prevalence of RA with ESRD in the USRDS in 2011 was 1.1%. There were significant differences in age, race, sex, and BMI category between the groups (p < 0.01). Diabetes (33.5%) and hypertension (30.6%) were the most common primary causes of ESRD in patients with RA. Amyloidosis, vasculitis, and analgesic nephropathy combined accounted for less than 10% of cases of ESRD. Prednisone was the most commonly filled medication that could be used to treat RA (45.9% of RA patients). Hydroxychloroquine was the most frequently filled DMARD (13.5%); biologics were uncommon (etanercept 2.5%, adalimumab 1.5%; golimumab, infliximab, anakinra, and abatacept <1%). Conclusions The co-occurrence of RA with ESRD was 1.1% in the USRDS by 2011. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Use of DMARDS other than hydroxychloroquine and biologics to treat RA in the setting of ESRD appears to be infrequent. Further prospective studies of treatment strategies for RA in ESRD are needed.

AB - Objectives To determine the frequency of end-stage renal disease (ESRD) in patients with rheumatoid arthritis (RA), the causes of ESRD, and the treatment of RA in the setting of ESRD. Methods Cross-sectional study of RA (N = 3754) and non-RA (N = 326,776) patients in the United States Renal Data System (USRDS) during 2011 (N = 330,530). The epidemiology of ESRD in RA was determined and the etiology of ESRD in patients with and without RA was compared. The frequency of patients with RA with at least one filled prescription for prednisone/prednisolone, a DMARD, and/or a biologic in 2011 was determined. Results The prevalence of RA with ESRD in the USRDS in 2011 was 1.1%. There were significant differences in age, race, sex, and BMI category between the groups (p < 0.01). Diabetes (33.5%) and hypertension (30.6%) were the most common primary causes of ESRD in patients with RA. Amyloidosis, vasculitis, and analgesic nephropathy combined accounted for less than 10% of cases of ESRD. Prednisone was the most commonly filled medication that could be used to treat RA (45.9% of RA patients). Hydroxychloroquine was the most frequently filled DMARD (13.5%); biologics were uncommon (etanercept 2.5%, adalimumab 1.5%; golimumab, infliximab, anakinra, and abatacept <1%). Conclusions The co-occurrence of RA with ESRD was 1.1% in the USRDS by 2011. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Use of DMARDS other than hydroxychloroquine and biologics to treat RA in the setting of ESRD appears to be infrequent. Further prospective studies of treatment strategies for RA in ESRD are needed.

KW - Biologics

KW - DMARDs

KW - End-stage renal disease

KW - Prednisone

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85014041344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014041344&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2016.07.016

DO - 10.1016/j.semarthrit.2016.07.016

M3 - Article

C2 - 27591827

AN - SCOPUS:85014041344

VL - 46

SP - 418

EP - 422

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 4

ER -